SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is capturing market attention as the quantum sector rallies following executive orders aimed at accelerating U.S. quantum research and cybersecurity migration. The community is actively debating the stock's volatility and its long-term potential as a pure-play hardware investment versus current concerns regarding insider selling and cash burn.

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. Its lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner on May 3, 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

Forte Biosciences is surging on significant investor interest following a heavily oversubscribed private placement, which the community is actively debating as a potential catalyst for continued momentum or a setup for future dilution. While some traders are riding the volatility for quick gains, others remain cautious, highlighting the disconnect between the company's early-stage pipeline and its rapid valuation expansion.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community braces for the upcoming July 29 FDA Advisory Committee meeting to review deramiocel, a critical therapy for Duchenne muscular dystrophy. Investors are actively debating the potential for a dual-label approval, navigating heavy short interest and recent patent litigation noise, while hopeful that the strong Phase 3 data will lead to a favorable outcome and subsequent stock revaluation.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is facing intense community debate as investors weigh strong fundamental growth metrics against persistent macro headwinds and technical resistance ahead of an earnings report that many view as a critical test. While bullish long-term holders focus on member expansion and the CEO's insider buying, bearish sentiment and short-term traders remain fixated on historical post-earnings volatility and broader market manipulation concerns.

Comcast Corp. engages in the provision of video, Internet, and phone services. It operates through the following segments: Residential Connectivity and Platforms, Business Services Connectivity, Media, Studios, and Theme Parks. The Residential Connectivity and Platforms segment consists of residential broadband and wireless services and Sky-branded entertainment television networks and advertising. The Business Service Connectivity segment offers broadband, wireline voice and wireless services through small to medium customers and large enterprises through the HFC network. The Media segment consists of NBCUniversal’s television and streaming platforms, including national, regional, and international cable networks. The Studios segment focuses on NBCUniversal’s film and television studio production and distribution operations. The Theme Parks segment operates Universal theme parks in Orlando, Florida, Hollywood, California, Osaka, Japan, and Beijing, China. The company was founded by Ralph Roberts in 1963 and is headquartered in Philadelphia, PA.

Comcast Corp - Ordinary Shares - Class A

Comcast Corp

Comcast is trending as investors react to the company's definitive plan to spin off its NBCUniversal and Sky media assets into a separate, publicly traded entity within the next year. The community is actively debating whether this restructuring will successfully unlock shareholder value and eliminate a conglomerate discount or if it will merely expose the new independent entities to increased risk.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony Corp. is seeing intense community discussion amid a broader sector-wide sell-off, with bulls emphasizing the company's status as a critical domestic supplier for the U.S. military. While investors debate the impact of potential market manipulation and defense-related supply chain catalysts, many remain focused on long-term growth despite recent price volatility.

SK hynix, Inc. engages in the manufacture and sale of semiconductor products. Its products include dynamic random access memory, flash memory, complementary metal oxide semiconductor image sensor, and others. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is rallying alongside the broader semiconductor sector following a massive $500 billion-plus partnership with NVIDIA to accelerate AI infrastructure and memory supply. The community is actively debating the sustainability of the stock's premium ADR pricing, the impact of upcoming IPOs in the memory space, and the long-term supply bottlenecks driving the AI memory boom.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors react to a significant multi-billion-dollar partnership with SK Group designed to secure long-term memory supply and scale AI infrastructure. The community is actively debating the sustainability of high AI capital expenditures and the impact of these massive infrastructure investments on Nvidia's future profitability.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors digest a negative CHMP opinion in Europe for YARTEMLEA, while the community actively debates whether the stock's recent volatility is driven by regulatory setbacks, concerns over competing therapies, or manipulative short-selling ahead of major J-code and NTAP catalysts. Despite the regulatory uncertainty, many long-term shareholders remain focused on the company's U.S. commercial launch, recent convertible debt repurchases, and the potential for a strategic buyout.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Singapore.

Seagate Technology Holdings Plc

Seagate Technology (STX) is seeing intense volatility as the memory and storage sector undergoes a high-beta repricing, driven by institutional re-accumulation and massive put-option activity suggesting mixed sentiment ahead of quarterly reports. Community discussions remain polarized between long-term bulls positioning for AI infrastructure expansion and bears concerned that the sector's parabolic run is losing momentum amid broad semiconductor profit-taking.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?

Here is how Allarity Therapeutics, Inc. (ALLR) and Alterity Therapeutics Limited - Sponsored ADR (ATHE) have performed compared to their sector so far this year.

Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder

Alterity Therapeutics advances ATH434 toward Phase 3 after FDA alignment on trial design for MSA, while shares decline in premarket trading.read more...

Alterity Therapeutics Gets Positive FDA Feedback On ATH434 Phase 3 Study

(RTTNews) - Alterity Therapeutics Limited (ATHE) on Monday said it received positive feedback from the U.S. Food and Drug Administration following a Type C meeting regarding its planned Phase 3 program for ATH434 in Multiple System Atrophy (MSA...

Alterity Therapeutics Gains FDA Backing For Phase 3 MSA Trial

(RTTNews) - Alterity Therapeutics (ATHE, ATH.AX) announced that it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA...

Alterity Therapeutics Announces Appointment Of Daniel Claassen As Chief Medical Advisor

(RTTNews) - Alterity Therapeutics Limited (ATHE), Wednesday announced the appointment of Daniel Claassen as Chief Medical Advisor, effective March 2026...

Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars

Equity

A 50mg dose of its ATH434 showed 8% reduction in clinical progression of early-stage multiple system atrophy vs. placebo.  

Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Alterity Therapeutics Ltd - ADR

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

ATHEAlterity Therapeutics Ltd - ADR

Fundamentals

Latest ATHE News